On January 20, 2000 The European Institute of Oncology in Milan, (EIO) and Pharmacia & Upjohn (PNU) reported to have entered in to a multi-year research collaboration and license agreement to collaborate on the discovery and characterisation of novel protein kinases and signal transduction pathways which could provide targets for new cancer drugs (Press release, Cancer Research Technology, JAN 20, 2000, View Source [SID1234523481]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Protein kinases are well-recognised molecular switches that can be selectively targeted by small drug molecules. Scientists at the Department of Experimental Oncology at EIO, chaired by Dr.Pier Giuseppe Pelicci, will apply their expertise in cell cycle and signal transduction to study the function of protein kinases in cancer cells. Scientists at PNU and Sugen, a biotechnology company recently acquired by PNU, will contribute their expertise in mechanism based drug discovery.

The agreement was arranged and negotiated on behalf of EIO by Cancer Research Ventures Limited (London. UK) the technology transfer company that was recently formed as a subsidiary of Cancer Research Campaign Technology Ltd.